Giuseppe Auteri
A5037355780- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Blood groups and transfusion
- Kruppel-like factors research
- Hemoglobinopathies and Related Disorders
- Renal Diseases and Glomerulopathies
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Heparin-Induced Thrombocytopenia and Thrombosis
- Bone and Joint Diseases
- Extracellular vesicles in disease
- Blood properties and coagulation
- Hemophilia Treatment and Research
- Autoimmune Bullous Skin Diseases
- Systemic Sclerosis and Related Diseases
- Dermatological and Skeletal Disorders
- Inflammatory Myopathies and Dermatomyositis
- Autoimmune and Inflammatory Disorders Research
- Venous Thromboembolism Diagnosis and Management
- T-cell and Retrovirus Studies
- Lipid metabolism and disorders
- Renal Transplantation Outcomes and Treatments
University of Bologna
2017-2024
Istituto di Ematologia di Bologna
2021-2024
Policlinico S.Orsola-Malpighi
2018-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2022
Azienda USL di Bologna
2020
University of Catania
2018
Background After discontinuing ruxolitinib, the outcome of patients with myelofibrosis reportedly has been poor. The authors investigated whether disease characteristics before receipt ruxolitinib may predict drug discontinuation in and reasons for discontinuation, phase at salvage therapies influence outcome. Methods A centralized electronic clinical database was created 20 European hematology centers, including laboratory data 524 who received myelofibrosis. Results At 3 years, 40.8% had...
Abstract Background Patients with cytopenic myelofibrosis (MF) have more limited therapeutic options and poorer prognoses compared patients the myeloproliferative phenotype. Aims Methods Prognostic correlates of phenotype were explored in 886 ruxolitinib‐treated primary/secondary MF (PMF/SMF) included RUX‐MF retrospective study. Cytopenia was defined as: leukocyte count <4 × 10 9 /L and/or hemoglobin <11/<10 g/dL (males/females) platelets <100 /L. Results Overall, 407 (45.9%) had...
Summary Up to 30% immune thrombocytopenia (ITP) patients achieve a sustained remission off‐treatment (SROT) after discontinuation of thrombopoietin receptor agonists (TPO‐RAs). Factors predictive response are lacking. Patients aged ≥18 years with newly diagnosed or persistent ITP were treated eltrombopag for 24 weeks. Primary end‐point was SROT: the proportion responders that able taper and discontinue maintaining during period observation (PO) six months. Secondary end‐points included...
Abstract Ruxolitinib is beneficial in patients with myelofibrosis (MF) and polycythemia vera (PV). Information on ruxolitinib adherence scant. The Adherence Myelofibrosis Polycythemia Vera (RAMP) prospective multicenter study (NCT06078319) included 189 ruxolitinib-treated patients. Patients completed the to Refills Medications Scale (ARMS) Distress Thermometer Problem List (DTPL) at earliest convenience, after registration study, later timepoints. At week-0, low (ARMS > 14) high distress...
Myelofibrosis (MF) is characterized by chronic inflammation and hyper-activation of the JAK-STAT pathway. Infections are one main causes morbidity/mortality. Therapy with Ruxolitinib (RUX), a JAK1/2 inhibitor, may further increase infectious risk. Monocytes critical players in inflammation/immunity through cytokine production release bioactive extracellular vesicles. However, functional behavior MF monocytes, particularly during RUX therapy, still unclear. In this study, we found that...
Immune thrombocytopenia (ITP) is an autoimmune disease that causes a drop in platelet count <100x109/L and it associated to bleeding symptoms psychological distress. It non-oncological hematological disease; however, research indicate significantly affects patients' well-being, yet support often excluded from standard care. The “Living under the Sword of Damocles” project offers patients caregivers while raising awareness among healthcare providers about ITP’s impact. Developed by...
Ruxolitinib (RUX), the first JAK1/JAK2 inhibitor approved for myelofibrosis (MF) therapy, has recently been associated with occurrence of second primary malignancies (SPMs), mainly lymphomas and non-melanoma skin cancers (NMSCs). We analyzed incidence, risk factors outcome SPMs in 700 MF patients treated RUX a real-world context. Median follow-up from starting was 2·9 years. Overall, 80 (11·4%) developed 87 after start. NMSCs were most common (50·6% cases). Multivariate analysis demonstrated...
After ruxolitinib discontinuation, the outcome of patients with myelofibrosis (MF) is poor scarce therapeutic possibilities.The authors performed a subanalysis an observational, retrospective study (RUX-MF) that included 703 MF treated to investigate 1) frequency and reasons for rechallenge, 2) its effects, 3) impact on overall survival.A total 219 (31.2%) discontinued ≥14 days survived ≥30 days. In 60 (27.4%), was rechallenged (RUX-again patients), whereas 159 (72.6%) it permanently...
PURPOSE Ruxolitinib improves splenomegaly and disease-related symptoms in most patients with myelofibrosis (MF), it has been associated a survival benefit higher-risk splenomegaly. Spleen volume reduction ruxolitinib-treated patients; however, its use as surrogate is limited. We hypothesized that an anti-inflammatory response to ruxolitinib would correlate improved patient outcomes. METHODS interrogated serum albumin, acute phase reactant marker of nutritional status 590 MF analyzed...
Abstract Background Anemia is frequently present in patients with myelofibrosis (MF), and it may be exacerbated by treatment the JAK2 ‐inhibitor ruxolitinib (RUX). Recently, a relevant blast phase (BP) incidence has been reported anemic MF unexposed to RUX. Methods The authors investigated of BP 886 RUX‐treated patients, included “RUX‐MF” retrospective study. Results rate ratio (IRR) was 3.74 per 100 patient‐years (3.74 %p‐y). At therapy start, Common Terminology Criteria for Adverse Events...
Most patients with myelofibrosis (MF) discontinue ruxolitinib (JAK1/JAK2 inhibitor) in the first 5 years of therapy due to failure. As therapeutic possibilities MF are expanding, it is critical identify predisposed early monotherapy failure and worse outcomes. We investigated predictors discontinuation death on 889 included “RUX-MF” retrospective study. Overall, 172 were alive after ≥5 (long-term ruxolitinib, LTR), 115 but off yrs (short-term RUX, STR), 123 died while <5 (early EDR). The...
The impact of ruxolitinib therapy on evolution to blast phase (BP) in patients with myelofibrosis (MF) is still uncertain. In 589 MF treated ruxolitinib, we investigated incidence and risk factors for BP described outcome according disease characteristics treatment strategy. After a median follow-up from start 3 years (range 0.1-7.6), 65 (11%) transformed during (93.8%) or after treatment. rate was 3.7 per 100 patient-years, comparably primary secondary (PMF/SMF) but significantly lower...
Summary Deferasirox (DFX) is used for the management of iron overload (IOL) in many haematological malignancies including myelofibrosis (MF). The ‘RUX‐IOL’ study retrospectively collected 69 MF patients treated with ruxolitinib (RUX) and DFX IOL to assess: safety, efficacy term chelation response (ICR) erythroid (ER), impact on overall survival combination therapy. RUX–DFX therapy was administered a median time 12.4 months (interquartile range 3.1–71.2). During treatment, 36 (52.2%) 34...
In polycythemia vera (PV), the prognostic relevance of an ELN-defined complete response (CR) to hydroxyurea (HU), predictors response, and patients’ triggers for switching ruxolitinib are uncertain. a real-world analysis, we evaluated their impact on clinical outcomes CR HU, correlations between partial or no (PR/NR) patient ruxolitinib. Among 563 PV patients receiving HU ≥12 months, 166 (29.5%) achieved CR, 264 PR, 133 NR. multivariate absence splenomegaly (p = 0.03), pruritus 0.002),...
Myelofibrosis (MF) and essential thrombocythaemia (ET) are clonal disorders with driver mutations (JAK2, CALR, MPL), chronic inflammation abnormalities in megakaryocyte development platelet activation. The absence of the 3 "driver" identifies triple negative (TN) patients. Ruxolitinib (a JAK1/2 inhibitor) reduces splenomegaly constitutional symptoms MF. However, over 50% patients fail to achieve a response or lose it time (Tefferi & Pardanani, 2015; Vainchenker et al, 2018). Extracellular...
Summary We analysed the impact of older age on management immune thrombocytopenia ( ITP ) in 465 adult patients diagnosed between 1995 and 2017 followed at our institution for a minimum 12 months. Over follow‐up 4248 patient‐years, front‐line corticosteroids therapy was required 334 (71·8%), mainly (85·3%) within 1 year from diagnosis. Need first‐, second‐ third‐line comparable younger (age ≥65 years, n = 154) patients. Older presented more frequently with severe haemorrhages, started higher...
In 816 patients with 2016 World Health Organization-defined polycythemia vera (PV) enrolled in a multicenter retrospective study, we investigated the predictive value of Charlson comorbidity index (CCI) and body mass (BMI) on thrombosis, progression to post-PV myelofibrosis (PPV-MF) survival. Patients were subgrouped according CCI = 0 (58.1%, no comorbidities) or ≥ 1 (41.9%) normal/underweight (BMI < 25, 54.5%) overweight/obesity 45.5%) at PV diagnosis. BMI was available for 529 patients....
Background The presence of peripheral blasts (PB) is a negative prognostic factor in patients with primary and secondary myelofibrosis (MF) PB ≥4% was associated particularly unfavorable prognosis. Ruxolitinib (RUX) the JAK1/2 inhibitor most used for treatment MF‐related splenomegaly symptoms. Its role has not been assessed correlation PB. Methods In 794 chronic‐phase MF treated RUX, we evaluated impact baseline percentage on response (spleen symptoms responses) outcome (RUX...